검색어: apl (영어 - 슬로베니아어)

(apl)
(apk)

leukocyte activation syndrome (apl differentiation syndrome):
sindrom aktivacije levkocitov (sindrom diferenciacije apl):

apl is the number of axles divided by the length over buffers.
apl je število osi, deljeno z dolžino prek odbojnikov.

the apl strategy paper shall also be transmitted to the european parliament for information.
strateški dokument o ppkm se prav tako pošlje v vednost evropskemu parlamentu.

the majority of patients do not require termination of trisenox therapy during treatment of the apl differentiation syndrome.
pri večini bolnikov med zdravljenjem sindroma diferenciacije apl ni potrebna prekinitev zdravljenja z zdravilom trisenox.

a significant amount of research has already been done into options for apl systems, including by the oecd18 and cedefop19.
veliko študij, zlasti v okviru oecd18 in cedefop19, preučuje načine za potrjevanje pridobljenega znanja.

apl is a unique type of myeloid leukaemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.
akutna promielocitna levkemija je posebna vrsta mieloidne levkemije, pri kateri se pojavljajo nenormalne bele krvne celice in neobičajne krvavitve in modrice.

leukocytosis occurred in 50% of patients with apl, as determined by haematology assessments, rather than adverse event reports.
to so ugotovili s hematološkimi raziskavami in ne s poročili o neželenih učinkih.

in post marketing experience, a differentiation syndrome, like retinoic acid syndrome, has also been reported for the treatment of malignancies other than apl with trisenox.
po začetku trženja so poročali o pancitopeniji; z uporabo zdravila trisenox za zdravljenje drugih malignosti kot apl so poročali o sindromu diferenciacije kot je sindrom retinojske kisline.

trisenox is indicated for induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (apl), characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor- alpha (pml/rar-alpha) gene.
zdravilo trisenox je indicirano za indukcijo remisije in konsolidacije pri odraslih bolnikih z akutno promielocitno levkemijo (apl – »acute promyelocytic leukaemia«) v relapsu ali refraktarni fazi, za katero je značilna prisotnost translokacije t(15;17) in/ali prisotnost gena za receptor za promielocitno levkemijo/retinojsko kislino alfa (pml/rar-alfa).